MedTrace Logo

Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients

NCT02622581 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 12400

Last updated 2025-02-18

No results posted yet for this study

Summary

Open, non-interventional, prospective, multi-center clinical research platform with the main objective to assess molecular biomarker testing, treatment and outcome of patients with NSCLC or SCLC in Germany

Conditions

  • Metastatic Non-small Cell Lung Cancer (NSCLC)
  • Non-small Cell Lung Cancer Metastatic
  • Non-small Cell Lung Cancer Stage II
  • Non Small Cell Lung Cancer Stage III
  • Small-cell Lung Cancer
  • Non-small Cell Lung Cancer Stage I

Interventions

OTHER

data collection

Baseline (demographic, clinical, tumor) characteristics, details on biomarker testing, including re-testing, treatment decision making, all systemic anticancer therapies including details, key data on radiotherapies, surgeries and specified supportive therapies, outcome (response, progression, survival), course of disease. Data will be documented at baseline and updated at least every three months.

Sponsors & Collaborators

Principal Investigators

  • Frank Griesinger, Prof. Dr. · Pius-Hospital Oldenburg

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-12-31
Primary Completion
2026-09-30
Completion
2027-12-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02622581 on ClinicalTrials.gov